Cargando…
A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer
Gastric cancer (GC) is the third leading cause of cancer deaths worldwide. Conventional chemotherapy has been proven useful to only a portion of the patients. Previous developed targeted drugs are more effective and tolerable than conventional drugs. Thus the development of novel drugs targeting mar...
Autores principales: | Wu, Wang, Yang, Zhiying, Xiao, Xing, An, Tailai, Li, Bo, Ouyang, Jun, Li, Huafu, Wang, Chunming, Zhang, Yawei, Zhang, Haiyong, He, Yulong, Zhang, Changhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086267/ https://www.ncbi.nlm.nih.gov/pubmed/32226516 http://dx.doi.org/10.7150/jca.40744 |
Ejemplares similares
-
Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2021) -
Retraction Note: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2022) -
Thioredoxin Reductase and its Inhibitors
por: Saccoccia, Fulvio, et al.
Publicado: (2014) -
Differences in the prognosis of gastric cancer patients of different sexes and races and the molecular mechanisms involved
por: Li, Huafu, et al.
Publicado: (2019) -
Self-Assembled Polymeric Micellar Nanoparticles as Nanocarriers for Poorly Soluble Anticancer Drug Ethaselen
por: Li, Xinru, et al.
Publicado: (2009)